FDA approves initial new weight-loss tablet in decade

<p>WASHINGTON (AP) — The <span>Food and Drug Administration</span> has authorized <span>Arena Pharmaceutical</span>‘s anti-obesity tablet Belviq, a initial new <span>prescription drug</span> for long-term <span>weight loss</span> to enter a U.S. marketplace in over a decade.</p>
<p>Despite usually achieving medium weight detriment in clinical studies, a drug seemed protected adequate to win a FDA’s endorsement, amid calls from doctors for new weight-loss treatments.</p>
<p>The group privileged a tablet Wednesday for adults who are portly or are overweight with during slightest one medical complication, such as diabetes or high cholesterol.</p>
<p>The FDA denied capitulation for Arena’s drug in 2010 after scientists lifted concerns about tumors that grown in animals complicated with a drug. The association resubmitted a drug with additional information progressing this year, and a FDA pronounced th...